Alzinova AB (“Alzinova” or the “Company”) announces that the Company’s global Phase II ADVANCE study with the vaccine candidate ALZ-101 has been accepted for a poster presentation at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The conference will take place in Boston, USA, on November 16–19, 2026.
The poster is entitled “ADVANCE: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Trial of ALZ-101 Active Immunotherapy in Early Alzheimer’s Disease” and describes the design of Alzinova’s global Phase II ADVANCE study with ALZ-101 for the treatment of early Alzheimer’s disease.
ADVANCE is a randomized, double-blind, placebo-controlled Phase II study in which the primary endpoint measures therapeutic effect in patients with early Alzheimer’s disease. Together with the contract research organization Worldwide Clinical Trials, Alzinova has completed the study kick-off and initiated the operational start-up phase, with the aim of enrolling the first participant around the turn of 2026/2027.
CTAD is an international scientific conference with a particular focus on clinical research and drug development in Alzheimer’s disease. The conference brings together researchers, clinicians, pharmaceutical companies and other stakeholders involved in the global development of new treatments against the disease.
Tord Labuda, CEO of Alzinova, comments:
“CTAD is an important international forum for clinical development in the Alzheimer’s field. For Alzinova, it provides an opportunity to increase awareness of ALZ-101 and ADVANCE among researchers, clinicians and other stakeholders in the field. As we now prepare the study to enroll its first participants, it is valuable to simultaneously establish ADVANCE within the international scientific discussion.”
An abstract will also be published in a special CTAD 2026 issue of The Journal of Prevention of Alzheimer’s Disease (JPAD), the official scientific journal of the CTAD conference.
About CTAD
Clinical Trials on Alzheimer’s Disease (CTAD) is an international conference focused on clinical research in Alzheimer’s disease. The 19th edition of CTAD will take place in Boston, USA, on November 16–19, 2026.
More information about the conference is available at: https://www.ctad-alzheimer.com/
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com